Considerations for long-acting antiretroviral therapy in older persons with HIV

O'Shea, Jesse G.; Cholli, Preetam; Heil, Emily L.; Buchacz, Kate

doi:10.1097/qad.0000000000003704

Cited by 2 publications

(1 citation statement)

References 89 publications

(153 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Furthermore, as PLWH age, increasing drug burden, polypharmacy, and metabolic changes, especially in the presence of renal or cardiac disease, may predispose patients to adverse drug toxicities. 186…”

Section: Drug To Drug Interactions and Polypharmacy In Older Plwhmentioning

confidence: 99%

Cardiac and Renal Comorbidities in Aging People Living With HIV

McCutcheon,

Nqebelele,

Murray

et al. 2024

Circulation Research

View full text Add to dashboard Cite

Contemporary World Health Organization data indicates that ≈39 million people are living with the human immunodeficiency virus. Of these, 24 million have been reported to have successfully accessed combination antiretroviral therapy. In 1996, the World Health Organization endorsed the widespread use of combination antiretroviral therapy, transforming human immunodeficiency virus infection from being a life-threatening disease to a chronic illness characterized by multiple comorbidities. The increased access to combination antiretroviral therapy has translated to people living with human immunodeficiency virus (PLWH) no longer having a reduced life expectancy. Although aging as a biological process increases exposure to oxidative stress and subsequent systemic inflammation, this effect is likely enhanced in PLWH as they age. This narrative review engages the intricate interplay between human immunodeficiency virus associated chronic inflammation, combination antiretroviral therapy, and cardiac and renal comorbidities development in aging PLWH. We examine the evolving demographic profile of PLWH, emphasizing the increasing prevalence of aging individuals within this population. A central focus of the review discusses the pathophysiological mechanisms that underpin the heightened susceptibility of PLWH to renal and cardiac diseases as they age.

show abstract

Section: Drug To Drug Interactions and Polypharmacy In Older Plwhmentioning

confidence: 99%